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The adoptive transfer of tumor-reactive T cells has shown
great promise in treating patients with metastatic cancer.
However, effective T cell responses are limited by the
availability of T cell growth factors such as IL-2 and
tumor-induced suppressive pathways. As tumor-induced
suppression may hamper cytokine responsiveness, we
hypothesized that combinatorial therapy providing exo-
genous cytokine with blockade of inhibitory pathways
would lead to synergistic anti-tumor responses. We evalu-
ated this hypothesis by treating mice with palpable B16
melanoma tumors with lymphodepletion and transfer of
activated, tumor-reactive CD8+ T cells (pmel-1 TCR trans-
genic). The persistence of the adoptively transferred
tumor-reactive CD8+ T cells was dramatically augmented
in the recipient mice with injections of an IL-15 superago-
nist (ALT-803) which, compared with IL-2, has greater
biological activity and does not expand T regulatory cells.
The ALT-803-treated mice also survived significantly
longer than the untreated mice. B16 melanoma tumor
cells were found to express PD-L1 and activated CD8+ T
cells have PD-1 on their surface. Thus, we also gave mice
anti-PD-L1 mAb treatment to block this PD-1/PD-L-1
inhibitory pathway. Our preliminary data suggest that
combinatorial therapy with anti-PD-L1 mAb led to syner-
gistic improvement in anti-tumor efficacy. We are now
determining the optimal timing and dosing of ALT-803
and anti-PD-L1 mAb therapy to confirm these results.
Currently, ALT-803 is in clinical trials for treating patients
with various solid and hematologic tumors. Our findings
suggest combinatorial therapy relieving T cell dysfunction
using checkpoint inhibitors and providing ALT-803
cytokine therapy may lead to substantially improved out-
comes over currently available therapies for patients with
metastatic cancer.
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